Background/Aims We aimed to define an optimal target population and drug-specific biomarkers that may predict dipeptidyl peptidase (DPP)-4 inhibitor responses in non-alcoholic fatty liver disease (NAFLD).
Methods An exploration study (study I) was performed using three different NAFLD models (basket study design; high-fat diet [HFD], methionine choline-deficient diet [MCD], and high-cholesterol Western diet [WD] models). RNA transcriptome analysis was performed on pre-studied liver tissues to identify biomarkers that could predict the response to DPP-4 inhibitors. In the validation study (study II), the HFD-induced NAFLD model was divided into high and low hepatic insulin-like growth factor binding protein 1 (Igfbp-1) groups based on the pre-study liver biopsy.
Results DPP-4 inhibitor attenuated the NAFLD activity score and fibrosis stage in the HFD model but not in the WD and MCD models. The overall response rate was 19% across the modified basket NAFLD trial and 42%, 25%, and 0% in the HFD, WD, and MCD models. Hepatic Igfbp-1 expression was higher in the responder group than in the non-responder group in pre-study biopsy samples. In contrast, hepatic Igfbp-1 expression was lower in the responder group than in the non-responder group in the end-study biopsy samples. DPP-4 inhibitor response rates were 83% and 17% in the baseline hepatic high Igfbp-1 and low Igfbp-1 groups, respectively. Hepatic messenger RNA Igfbp-1 expression was positively correlated with serum IGFBP-1 levels.
Conclusions The DPP-4 inhibitor response was higher in the HFD phenotype and pre-treatment levels of hepatic or serum IGFBP-1 were high.
Citations
Citations to this article as recorded by
Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis Gina Ryu, Eileen Laurel Yoon, Wankyu Kim, Dae Won Jun Diagnostics.2025; 15(3): 342. CrossRef
New clinical trial design in precision medicine: discovery, development and direction Xiao-Peng Duan, Bao-Dong Qin, Xiao-Dong Jiao, Ke Liu, Zhan Wang, Yuan-Sheng Zang Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Ticagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease Eun Jeoung Lee, Seung Min Lee, Ju Hee Oh, Hye Young Kim, Waqar Khalid Saeed, Hyun Sung Kim, Dae Won Jun Nutrients.2024; 16(7): 920. CrossRef
Discovery of Nine Dipeptidyl Peptidase-4 Inhibitors from Coptis chinensis Using Virtual Screening, Bioactivity Evaluation, and Binding Studies Zixi Zhao, Ruonan Ma, Yuqing Ma, Liqiang Zhao, Lele Wang, Yuzhen Fang, Yuxin Zhang, Xia Wu, Xing Wang Molecules.2024; 29(10): 2304. CrossRef
DPP-IV as a potential candidate in anti-obesity and obesity-related diseases treatment Xin Guo, Huolun Feng, Liyang Cai, Jiabin Zheng, Yong Li Biomedicine & Pharmacotherapy.2024; 180: 117464. CrossRef
From NAFLD to HCC: Advances in noninvasive diagnosis Qinchen Xu, Maoxiao Feng, Yidan Ren, Xiaoyan Liu, Huiru Gao, Zigan Li, Xin Su, Qin Wang, Yunshan Wang Biomedicine & Pharmacotherapy.2023; 165: 115028. CrossRef
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review Rong Xu, Difei Lian, Yan Xie, Zhilei Chen, Yan Wang, Lin Mu, Yuan Wang, Baoyu Zhang Frontiers in Bioscience-Landmark.2023;[Epub] CrossRef
Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials Joel Yeh Siang Chen, Damien Chua, Carissa Odelia Lim, Wan Xi Ho, Nguan Soon Tan International Journal of Molecular Sciences.2022; 24(1): 158. CrossRef
First
Prev
